Morag Park
Overview
Explore the profile of Morag Park including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
7310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lewis K, La Selva R, Maldonado E, Annis M, Najyb O, Cepeda Canedo E, et al.
Redox Biol
. 2024 Jan;
70:103028.
PMID: 38211442
Significant efforts have focused on identifying targetable genetic drivers that support the growth of solid tumors and/or increase metastatic ability. During tumor development and progression to metastatic disease, physiological and...
12.
Goyette M, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault M, et al.
Cell Rep
. 2023 Dec;
42(12):113604.
PMID: 38100352
No abstract available.
13.
Taifour T, Attalla S, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H, et al.
Immunity
. 2023 Dec;
56(12):2755-2772.e8.
PMID: 38039967
In triple-negative breast cancer (TNBC), stromal restriction of CD8 T cells associates with poor clinical outcomes and lack of responsiveness to immune-checkpoint blockade (ICB). To identify mediators of T cell...
14.
Flores-Torres S, Dimitriou N, Pardo L, Kort-Mascort J, Pal S, Peza-Chavez O, et al.
ACS Appl Mater Interfaces
. 2023 Jul;
15(28):33250-33262.
PMID: 37404007
The immune response against a tumor is characterized by the interplay among components of the immune system and neoplastic cells. Here, we bioprinted a model with two distinct regions containing...
15.
Attalla S, Boucher J, Proud H, Taifour T, Zuo D, Sanguin-Gendreau V, et al.
Cancer Immunol Res
. 2023 Jun;
11(9):1184-1202.
PMID: 37311021
The tumor-immune microenvironment (TIME) is a critical determinant of therapeutic response. However, the mechanisms regulating its modulation are not fully understood. HER2Δ16, an oncogenic splice variant of the HER2, has...
16.
Zhu X, Fu Z, Chen S, Ong D, Aceto G, Ho R, et al.
Nat Commun
. 2023 May;
14(1):2894.
PMID: 37210563
SMARCA4 (BRG1) and SMARCA2 (BRM) are the two paralogous ATPases of the SWI/SNF chromatin remodeling complexes frequently inactivated in cancers. Cells deficient in either ATPase have been shown to depend...
17.
Quail D, Park M, Welm A, Ekiz H
Cold Spring Harb Perspect Med
. 2023 May;
14(2).
PMID: 37188526
Our ability to interrogate the tumor immune microenvironment (TIME) at an ever-increasing granularity has uncovered critical determinants of disease progression. Not only do we now have a better understanding of...
18.
Xue Y, Morris J, Yang K, Fu Z, Zhu X, Johnson F, et al.
Nat Commun
. 2023 Mar;
14(1):1552.
PMID: 36944611
No abstract available.
19.
Nandi I, Smith H, Sanguin-Gendreau V, Ji L, Pacis A, Papavasiliou V, et al.
J Clin Invest
. 2023 Feb;
133(7).
PMID: 36795481
Activation of the tyrosine kinase c-Src promotes breast cancer progression and poor outcomes, yet the underlying mechanisms are incompletely understood. Here, we have shown that deletion of c-Src in a...
20.
Mihalcioiu C, Li J, Badescu D, Camirand A, Kremer N, Bertos N, et al.
Am J Cancer Res
. 2023 Feb;
13(1):25-44.
PMID: 36777514
Circulating tumor cells (CTCs) represent cells shed from the primary tumor or metastatic sites and can be used to monitor treatment response and tumor recurrence. However, CTCs circulate in extremely...